China's new lung cancer early diagnosis reagent kit approved for market launch
According to the Hangzhou Institute of Medicine, Chinese Academy of Sciences, thirteen types of lung cancer-related antibody detection kits (flow cytometry immunoassay), developed by the research team of the institute, have officially obtained Class III medical device registration certificates from the National Medical Products Administration, which is expected to improve the early diagnosis rate of lung cancer. (Xinhua News Agency)
Source: Wallstreetcn The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments